[HTML][HTML] Role of endometrial autophagy in physiological and pathophysiological processes
S Yang, H Wang, D Li, M Li - Journal of Cancer, 2019 - ncbi.nlm.nih.gov
Endometrium is the mucosal lining of the uterus which expressed a cyclic process of
proliferation, secretion and scaling under the control of hormones secreted by the ovary, and …
proliferation, secretion and scaling under the control of hormones secreted by the ovary, and …
[HTML][HTML] Current locoregional therapies and treatment strategies in hepatocellular carcinoma
L Cardarelli-Leite, A Hadjivassiliou, D Klass… - Current …, 2020 - ncbi.nlm.nih.gov
Locoregional therapies (lrt s) play an important role in the treatment of hepatocellular
carcinoma (hcc), with the aim of increasing overall survival while preserving liver function …
carcinoma (hcc), with the aim of increasing overall survival while preserving liver function …
Clinical and Dosimetric Implications of Calculating Lung Shunt Fraction for Hepatic 90Y Radioembolization Using SPECT/CT Versus Planar Scintigraphy
L Struycken, M Patel, P Kuo… - American Journal of …, 2022 - Am Roentgen Ray Soc
BACKGROUND. Accurate assessment of hepatopulmonary shunting, typically performed by
planar scintigraphy, is critical in planning 90Y radioembolization. High lung shunt fractions …
planar scintigraphy, is critical in planning 90Y radioembolization. High lung shunt fractions …
Reduction of Hepatopulmonary and Intrahepatic Shunts after Treatment with Sorafenib in Hepatocellular Carcinoma Patients
HT Balli, K Aikimbaev, IG Burak, UA Pehlivan… - CardioVascular and …, 2022 - Springer
Purpose To investigate the reduction of elevated shunts after treatment with sorafenib in
hepatocellular carcinoma (HCC) patients planned for transarterial radioembolization …
hepatocellular carcinoma (HCC) patients planned for transarterial radioembolization …
Short-term oral sorafenib for therapy of intratumoral shunts of hepatocellular carcinoma to enable intraarterial treatment
J Thüring, M Zimmermann, P Bruners… - Cardiovascular and …, 2019 - Springer
Introduction Significant intratumoral shunts between tumor-supplying arteries and portal or
liver veins are a contraindication for transarterial therapy of HCC because interventional …
liver veins are a contraindication for transarterial therapy of HCC because interventional …